On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.

Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking ...